ClinicalTrials.gg
CompletedNCT02040779Updated Nov 9, 2021Results posted

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

A Phase 3 interventional study of Beclomethasone dipropionate breath-actuated inhaler and Placebo breath-actuated inhaler in Persistent Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 47 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
14th of 40
273 · median 67
Started
2013
with 4 others
Phase 3
20 of 40
none open now
Registered
26th of 40
by date
Lead sponsor
7 of 40
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 40 studies testing beclomethasone in Asthma, this one is the 14th largest by enrollment, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 26th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after a 14- to 21-day run-in period. Participants and investigators will remain blinded to randomized treatment assignment during the study

03

Conditions studied

  • Persistent Asthma

Browse trials for

Keywords

  • asthma
  • breath-actuated inhaler
  • beclomethasone
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severity of Disease: The patient has persistent asthma, with an (FEV1) 40%-85% of the value predicted for age, height, sex, and race as per the National Health and Nutrition Examination Survey (NHANES III) reference values at screening visit (SV) (Hankinson et al 1999).
  • Current asthma therapy: The patient is currently being treated with 1 of the following:

    1. inhaled (ICSs) at a stable daily dose of less than or equal to 220 mcg/day fluticasone propionate via metered dose inhaler (MDI) or equivalent for a minimum of 4 weeks (28 days) before screening visit, or 2) a stable daily dosage of non-corticosteroid therapy, including leukotriene modifiers, theophylline, chromones, or short-acting beta-2 agonists (SABAs) alone or in combination for a minimum of 4 weeks (28 days) before screening visit (SV).
  • Reversibility of disease: The patient has demonstrated at least 15% and at least 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2-4 inhalations of albuterol/salbutamol hydrofluoroalkane (HFA) MDI (90 mcg ex-actuator) or equivalent at SV or on retesting. - Other criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The patient has a history of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures.
  • The patient is a pregnant or lactating female or plans to become pregnant.
  • The patient has a known to any or any of the in the study drug or rescue medication formulation.
  • The patient currently smokes or has a smoking history of 10 pack-years or more (a pack-year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year.
  • The patient has had an asthma exacerbation requiring oral corticosteroids within 1 month before SV, or has had any hospitalization for asthma within 2 months before SV.
  • The patient has historical or current evidence of a disease. Significant disease is defined as any disease that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
  • Other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
273 participants (actual)

Study arms

  • Experimental
    BDP 80 mcg BAI

    40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.

    Drug: Beclomethasone dipropionate breath-actuated inhaler · Drug: albuterol/salbutamol

  • Experimental
    BDP 160 mcg BAI

    80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.

    Drug: Beclomethasone dipropionate breath-actuated inhaler · Drug: albuterol/salbutamol

  • Placebo comparator
    Placebo BAI

    Placebo breath-actuated inhaler (BAI) twice daily.

    Drug: Placebo breath-actuated inhaler · Drug: albuterol/salbutamol

Interventions

  • Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.

    Also known as: BDP

  • DrugPlacebo breath-actuated inhaler

    Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.

  • Drugalbuterol/salbutamol

    Drug page: Albuterol

    Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period

    Also known as: bronchodilators

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received

    The primary efficacy variable was the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) FEV1 AUEC(0-12wk). Pulmonary function measurements such as FEV1 were obtained electronically by spirometry at the randomization visit (Day 1), each treatment visit (Weeks 2, 4, 8 and 12) and any unscheduled visit (such as the early termination visit). This summary is based on observed values recorded as 'best attempt'. The least-square (LS) means, difference of LS means and its 95% confidence interval (CI), and p-value represent the results obtained from the analysis of covariance with covariate adjustment for baseline, sex, age, current asthma therapy, and treatment.

    Time frame: Baseline (Day 1 predose), weeks 2, 4, 8 and 12

Secondary outcomes

  1. Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period

    Change from baseline in the weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF by handheld spirometer over the 12-week treatment period. PEF were determined twice daily, in the morning and in the evening, before administration of study drug or rescue medications. A handheld spirometer was provided to patients and used to determine the morning and evening PEF throughout the study. The spirometer was programmed to record the highest PEF obtained from 3 valid attempts. Baseline was defined as the average of recorded trough morning PEF assessments over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12

  2. Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

    A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12

  3. Change From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12

    Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. The LS means, difference of LS means and its 95% CI, and p-value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week and treatment by week interaction. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including morning usage at the randomization visit.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12

  4. Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

    Asthma symptom scores were recorded in the patient's diary each morning and evening before determining FEV1 and PEF and before administration of study or rescue medications. The Daytime Symptom Score was recorded in the evening on a scale of 0 (No symptoms during the day) to 5 (Symptoms so severe that I could not go to work or perform normal daily activities) plus the Nighttime Symptom Score in the morning on a scale of 0 (No symptoms during the night) to 4 (Symptoms so severe that I did not sleep at all) for a total score range of 0-9. Baseline was defined as the average of recorded daily asthma symptom scores (average of daytime and nighttime score) over the 7 days prior to the first dose of study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% CI, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy,

    Time frame: Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12

  5. Kaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

    The time to patient study drug treatment withdrawal due to worsening asthma was defined as the number of days elapsed from the date of randomization to the date of withdrawal due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

    Time frame: Treatment period: daily from Day 1 up to Week 12

  6. Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

    A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

    Time frame: Treatment period: Day 1 up to Week 12

  7. Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent 1 of the outcomes listed in this definition.

    Time frame: Day 1 up to Week 12

  8. Participants With Potentially Clinically Relevant Abnormal Vital Sign Results During the Treatment Period

    Criteria for the select vital signs that showed a potentially clinically relevant abnormal result are: * Sitting systolic BP (low); \<=90 mm Hg and decrease of \>=20 mm Hg from baseline * Sitting diastolic BP (high): \>=105 mm Hg and increase of \>=15 mm Hg from baseline Baseline is defined as the last available assessment prior to the first dose of double-blind study treatment (usually Day 1 predose).

    Time frame: Baseline (Day 1 predose), Visits at weeks 2, 4, 8, 12

  9. Participants With Findings During Oropharyngeal Examination During Treatment

    Oropharyngeal examinations were performed at every visit by a qualified healthcare professional: during treatment visits are summarized. Any visual evidence of oral candidiasis during the treatment period of the study was evaluated by obtaining and analyzing a swab of the suspect area for culturing. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation.

    Time frame: Visits at weeks 2, 4, 8, 12

07

Results

Posted Dec 11, 2017

Participant flow

For this study, 47 sites were activated and screened at least 1 patient, 44 sites screened at least 1 patient who entered the run-in period, and 43 sites randomly assigned a patient. Overall, 273 patients were randomly assigned to treatment

Participant flow — Overall Study
MilestonePlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Started919092
Full analysis set (fas)908892
Completed798388
Not completed1274
Withdrew: Adverse event100
Withdrew: Withdrawal by subject413
Withdrew: Non-compliance010
Withdrew: Protocol violation210
Withdrew: Lost to follow-up121
Withdrew: Lack of efficacy420

Outcome measures

PrimaryStandardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received

The primary efficacy variable was the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) FEV1 AUEC(0-12wk). Pulmonary function measurements such as FEV1 were obtained electronically by spirometry at the randomization visit (Day 1), each treatment visit (Weeks 2, 4, 8 and 12) and any unscheduled visit (such as the early termination visit). This summary is based on observed values recorded as 'best attempt'. The least-square (LS) means, difference of LS means and its 95% confidence interval (CI), and p-value represent the results obtained from the analysis of covariance with covariate adjustment for baseline, sex, age, current asthma therapy, and treatment.

Time frame:
Baseline (Day 1 predose), weeks 2, 4, 8 and 12
Reported as:
Least squares mean · liters
Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received
litersPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received0.048 ± 0.02520.171 ± 0.02540.164 ± 0.0248
Statistical analysis
  • Placebo BAI vs BDP 160 mcg BAI · ANCOVA · p = 0.0010 (ANCOVA model with effects due to baseline trough morning FEV1, sex, age, current protocol-allowed asthma therapy (ICS or non-corticosteroid therapy) at the time of screening visit and during the run-in period and treatment.) · Lsm difference: 0.116 · 95% CI 0.048 to 0.185BDP 160 mcg BAI - Placebo BAI
  • Placebo BAI vs BDP 80 mcg BAI · ANCOVA · p = 0.0005 (ANCOVA model with effects due to baseline trough morning FEV1, sex, age, current protocol-allowed asthma therapy (ICS or non-corticosteroid therapy) at the time of screening visit and during the run-in period and treatment.) · Lsm difference: 0.124 · 95% CI 0.054 to 0.193BDP 80 mcg BAI - Placebo BAI
SecondaryChange From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period

Change from baseline in the weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF by handheld spirometer over the 12-week treatment period. PEF were determined twice daily, in the morning and in the evening, before administration of study drug or rescue medications. A handheld spirometer was provided to patients and used to determine the morning and evening PEF throughout the study. The spirometer was programmed to record the highest PEF obtained from 3 valid attempts. Baseline was defined as the average of recorded trough morning PEF assessments over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Reported as:
Least squares mean · L/minute
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period
L/minutePlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period-0.795 ± 2.822412.849 ± 2.82417.116 ± 2.7735
Statistical analysis
  • Placebo BAI vs BDP 160 mcg BAI · mixed model for repeated measures · p = 0.0443 (a priori threshold for significance of 0.05.) · Lsm difference: 7.911 · 95% CI 0.202 to 15.621BDP 160 mcg BAI - Placebo BAI
  • Placebo BAI vs BDP 80 mcg BAI · mixed model for repeated measures · p = 0.0007 (a priori threshold for significance of 0.05.) · Lsm difference: 13.645 · 95% CI 5.843 to 21.446BDP 160 mcg BAI - Placebo BAI
SecondaryChange From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Reported as:
Least squares mean · L/minute
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
L/minutePlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period-0.797 ± 3.038010.105 ± 35.05074.608 ± 2.9908
Statistical analysis
  • Placebo BAI vs BDP 160 mcg BAI · mixed model for repeated measures · p = 0.2014 (a priori threshold for significance of 0.05.) · Lsm difference: 5.405 · 95% CI -2.905 to 13.715BDP 160 mcg BAI - Placebo BAI
  • Placebo BAI vs BDP 80 mcg BAI · mixed model for repeated measures · p = 0.0112 (a priori threshold for significance of 0.05.) · Lsm difference: 10.902 · 95% CI 2.500 to 19.303BDP 160 mcg BAI - Placebo BAI
SecondaryChange From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12

Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. The LS means, difference of LS means and its 95% CI, and p-value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week and treatment by week interaction. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including morning usage at the randomization visit.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Reported as:
Least squares mean · inhalations
Change From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12
inhalationsPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Change From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12-0.010 ± 0.1162-0.368 ± 0.1155-0.398 ± 0.1153
Statistical analysis
  • Placebo BAI vs BDP 160 mcg BAI · mixed model for repeated measures · p = 0.0175 (a priori threshold for significance of 0.05.) · Lsm difference: -0.388 · 95% CI -0.708 to -0.068BDP 160 mcg BAI - Placebo BAI
  • Placebo BAI vs BDP 80 mcg BAI · mixed model for repeated measures · p = 0.0285 (a priori threshold for significance of 0.05.) · Lsm difference: -0.358 · 95% CI -0.678 to -0.038BDP 80 mcg BAI - Placebo BAI
SecondaryChange From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

Asthma symptom scores were recorded in the patient's diary each morning and evening before determining FEV1 and PEF and before administration of study or rescue medications. The Daytime Symptom Score was recorded in the evening on a scale of 0 (No symptoms during the day) to 5 (Symptoms so severe that I could not go to work or perform normal daily activities) plus the Nighttime Symptom Score in the morning on a scale of 0 (No symptoms during the night) to 4 (Symptoms so severe that I did not sleep at all) for a total score range of 0-9. Baseline was defined as the average of recorded daily asthma symptom scores (average of daytime and nighttime score) over the 7 days prior to the first dose of study treatment, including the morning assessment at the randomization visit. The LS means, difference of LS means and its 95% CI, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy,

Time frame:
Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
units on a scalePlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period-0.166 ± 0.0460-0.293 ± 0.0463-0.304 ± 0.0454
Statistical analysis
  • Placebo BAI vs BDP 160 mcg BAI · mixed model for repeated measures · p = 0.0335 (a priori threshold for significance of 0.05.) · Lsm difference: -0.137 · 95% CI -0.263 to -0.011BDP 160 mcg BAI - Placebo BAI
  • Placebo BAI vs BDP 80 mcg BAI · mixed model for repeated measures · p = 0.0509 (a priori threshold for significance of 0.05.) · Lsm difference: -0.127 · 95% CI -0.255 to 0.001BDP 80 mcg BAI - Placebo BAI
SecondaryKaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

The time to patient study drug treatment withdrawal due to worsening asthma was defined as the number of days elapsed from the date of randomization to the date of withdrawal due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

Time frame:
Treatment period: daily from Day 1 up to Week 12
Reported as:
Median · days
Kaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
daysPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Kaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment PeriodNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

Time frame:
Treatment period: Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
ParticipantsPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period520
Statistical analysis
  • Placebo BAI vs BDP 80 mcg BAI · Log Rank · p = 0.2384
  • Placebo BAI vs BDP 160 mcg BAI · Log Rank · p = 0.0208
SecondaryParticipants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent 1 of the outcomes listed in this definition.

Time frame:
Day 1 up to Week 12
Reported as:
Count of participants · Participants
Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
>=1 adverse event283226
>=1 severe TEAE200
>=1 treatment-related TEAE112
>=1 serious TEAE100
>=1 AE causing discontinuation100
SecondaryParticipants With Potentially Clinically Relevant Abnormal Vital Sign Results During the Treatment Period

Criteria for the select vital signs that showed a potentially clinically relevant abnormal result are: * Sitting systolic BP (low); \<=90 mm Hg and decrease of \>=20 mm Hg from baseline * Sitting diastolic BP (high): \>=105 mm Hg and increase of \>=15 mm Hg from baseline Baseline is defined as the last available assessment prior to the first dose of double-blind study treatment (usually Day 1 predose).

Time frame:
Baseline (Day 1 predose), Visits at weeks 2, 4, 8, 12
Reported as:
Count of participants · Participants
Participants With Potentially Clinically Relevant Abnormal Vital Sign Results During the Treatment Period
ParticipantsPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
>=1 abnormality222
Sitting systolic BP (low)111
Sitting diastolic BP (high)111
SecondaryParticipants With Findings During Oropharyngeal Examination During Treatment

Oropharyngeal examinations were performed at every visit by a qualified healthcare professional: during treatment visits are summarized. Any visual evidence of oral candidiasis during the treatment period of the study was evaluated by obtaining and analyzing a swab of the suspect area for culturing. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation.

Time frame:
Visits at weeks 2, 4, 8, 12
Reported as:
Count of participants · Participants
Participants With Findings During Oropharyngeal Examination During Treatment
ParticipantsPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
>=1 evidence of oral candidiasis appearance002
Participants with a positive culture001

Adverse events

Collected over Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo BAI0/91 (0%)1/91 (1.1%)0/91 (0%)
BDP 80 mcg BAI0/90 (0%)0/90 (0%)0/90 (0%)
BDP 160 mcg BAI0/92 (0%)0/92 (0%)0/92 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo BAIBDP 80 mcg BAIBDP 160 mcg BAI
PneumoniaInfections and infestations1/910/900/92
AsthmaRespiratory, thoracic and mediastinal disorders1/910/900/92

Baseline characteristics

Intent-to-treat (ITT) Population

Age, Continuous
Age, Continuous(years)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Mean37.2 ± 14.8238.8 ± 15.0237.4 ± 16.0537.8 ± 15.27
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Female465456156
Male453636117
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
American Indian or Alaska Native0000
Asian3216
Native Hawaiian or Other Pacific Islander1001
Black or African American13171444
White736472209
More than one race0000
Unknown or Not Reported17513
Weight
Weight(kg)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Mean82.27 ± 23.84885.30 ± 22.38280.29 ± 20.57782.60 ± 22.316
Height
Height(cm)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Mean169.28 ± 9.473170.88 ± 10.447168.78 ± 8.657169.64 ± 9.554
Body Mass Index
Body Mass Index(kg/m^2)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Mean28.383 ± 6.905129.266 ± 7.937128.136 ± 6.775128.591 ± 7.2109
Duration of Asthma
Duration of Asthma(Participants)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
<3 months0000
3 months to <6 months0101
6 months to <1 year1102
1 year to < 5 years44210
5 years to <10 years981027
10 years to <15 years12161846
>=15 years656062187
Current Asthma Therapy
Current Asthma Therapy(Participants)Placebo BAIBDP 80 mcg BAIBDP 160 mcg BAITotal
Inhaled corticosteroid353435104
Non-corticosteroid565657169
08

Study locations

47 sites
  • Teva Investigational Site 12813
    Huntington Beach, California, United States
  • Teva Investigational Site 10944
    Mission Viejo, California, United States
  • Teva Investigational Site 10946
    Orange, California, United States
  • Teva Investigational Site 10963
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 10960
    San Diego, California, United States
  • Teva Investigational Site 10973
    San Diego, California, United States
  • Teva Investigational Site 10975
    San Jose, California, United States
  • Teva Investigational Site 10948
    Centennial, Colorado, United States
  • Teva Investigational Site 10958
    Centennial, Colorado, United States
  • Teva Investigational Site 10957
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 12814
    Sarasota, Florida, United States
  • Teva Investigational Site 10962
    Tallahassee, Florida, United States
  • Teva Investigational Site 12809
    Savannah, Georgia, United States
  • Teva Investigational Site 10947
    Indianapolis, Indiana, United States
  • Teva Investigational Site 10943
    Iowa City, Iowa, United States
  • Teva Investigational Site 10954
    Baltimore, Maryland, United States
  • Teva Investigational Site 12940
    Bethesda, Maryland, United States
  • Teva Investigational Site 10955
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10941
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 10970
    Columbia, Missouri, United States
  • Teva Investigational Site 10968
    Rolla, Missouri, United States
  • Teva Investigational Site 10972
    Bozeman, Montana, United States
  • Teva Investigational Site 12941
    Missoula, Montana, United States
  • Teva Investigational Site 10942
    Bellevue, Nebraska, United States
  • Teva Investigational Site 10959
    Skillman, New Jersey, United States
  • Teva Investigational Site 10945
    Raleigh, North Carolina, United States
  • Teva Investigational Site 12810
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10974
    Sylvania, Ohio, United States
  • Teva Investigational Site 12805
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12942
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10951
    Tulsa, Oklahoma, United States
  • Teva Investigational Site 10940
    Lake Oswego, Oregon, United States
  • Teva Investigational Site 10952
    Medford, Oregon, United States
  • Teva Investigational Site 10956
    Portland, Oregon, United States
  • Teva Investigational Site 12939
    Pittsburgh, Pennsylvania, United States
  • Teva Investigational Site 12806
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 12811
    Knoxville, Tennessee, United States
  • Teva Investigational Site 10969
    Austin, Texas, United States
  • Teva Investigational Site 12812
    Boerne, Texas, United States
  • Teva Investigational Site 10949
    Dallas, Texas, United States
  • Teva Investigational Site 10953
    El Paso, Texas, United States
  • Teva Investigational Site 12807
    Houston, Texas, United States
  • Teva Investigational Site 10950
    New Braunfels, Texas, United States
  • Teva Investigational Site 10961
    San Antonio, Texas, United States
  • Teva Investigational Site 12808
    Waco, Texas, United States
  • Teva Investigational Site 10967
    Seattle, Washington, United States
  • Teva Investigational Site 10964
    Greenfield, Wisconsin, United States
09

References and documents

Publications

  • Hampel FC Jr, Carr W, Gillespie M, Small CJ. Evaluation of beclomethasone dipropionate (80 and 160 micrograms/day) delivered via a breath-actuated inhaler for persistent asthma. Allergy Asthma Proc. 2017 Nov 8;38(6):419-430. doi: 10.2500/aap.2017.38.4089. Epub 2017 Sep 8. PubMed 28886758 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 2 years 11 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2014
First posted
Jan 20, 2014
Start
Dec 26, 2013
Primary completionActual
Dec 24, 2014
CompletionActual
Dec 24, 2014
Results delay requested
May 21, 2015
Results first posted
Dec 11, 2017
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02040779
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
Dec 26, 2013
Primary completion
Dec 24, 2014
Completion
Dec 24, 2014
Results posted
Dec 11, 2017
Last update
Nov 9, 2021

Study contacts

Medical Director, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion